america
thought beyond
ignor fault line
provis ink paper
karuna initi outperform
color fundament focu call bank
check monotherapi
potenti address
posit classical-lung updat aacr
first take result
valuat keep us sidelin
analyst certif import disclosur see
thought beyond
share under-perform med-tech peer ytd versu high elect procedur
exposur case delay doubt drive factor underappreci support
element believ includ digit health program current lower exposur capital-intens robot
look forward state begun plan restart elect procedur could see rel benefit govern
restrict eas first elect outpati procedur estim knees/hip perform outpt includ
asc hospit outpt increas unemploy loss health insur bear watch saw
situat remain fluid recent consensu full-year estim impli slightli lower unemploy level versu
near-term forecast higher
ignor fault line
geolog fault fracture/discontinu volum rock across signific yet gradual displac
due rock-mass movement time great econom strain financi fault-lin tendenc slowli manifest
catch investor unprepar given v-shape recoveri increasingli unlik u-shap recoveri hope see
grow near-term risk investor consid specif increas evid deal/pay push-out
shorter contract durat extend free-trials/pric concess risk somewhat expect investor
lower bill expect unsur magnitud durat disrupt yet see financi strain
move first-lin second-lin vertic make grow likelihood deeper spend cut increas knowledg
worker layoff deceler digitization/transform project ultim see near-term risk across group
emphas long-term natur rate
client follow work close consum growth e-commerce space know point
improv underli health use car marketplac structur improv lead digit enabl
oper outperform-r carvana care monitor assess myriad data
point mon apr caught phone san francisco ca-bas on-line use car seller shift includ
compani co-found co-ceo georg arison detail full report releas today comment insight
mr arison suggest clearli underli power nimbl come shift model potenti
signific recoveri use car busi broadli current headwind abat
provis ink paper
stock came pressur result announc investor ponder one read
provis loan loss arriv bank took bigger provis bank
conserv wors shape fact matter one read anyth
provis jp morgan chairman jami dimon word ink paper creat
destroy singl dollar capit move one side balanc sheet creat destroy
capit pre-provis earn ppe net charge-off nco cours rise provis loss
cumul expect bank composit gener ppe versu loss
continu recommend gs ms slightli rais price target base slightli
higher ep estim higher market multipl see exhibit full report date
karuna initi outperform
initi outperform rate pt view emerg leader schizophrenia
psychosi lead develop candid karxt coformul xanomelin trospium chlorid base novel
differenti moa target muscarin receptor strong clinic data believ uniqu moa karxt enabl
potenti superior efficaci toler current avail atyp antipsychot compris market
primarili develop karxt schizophrenia adult dementia-rel psychosi drp pivot
program schizophrenia expect initi follow compel result safeti studi drp
reads-out estim peak sale schizophrenia drp
color fundament focu call bank
check monotherapi
monday dr ryan sullivan mgh provid updat phase virtual meet
two object respons report last month see standout early-stag immuno-oncolog stori significantli
amplifi recent big biopharma interest tigit close relat immun checkpoint previous announc partial
respons pr remain on-going includ one monotherapi arm last week view safeti data
trial support move triplet combin nivo anti-tigit part compugen collabor
bristol-my squibb translat data monotherapi dose expans cohort expect could
cement pvrig statu bona fide immun checkpoint reiter op pt
maintain revenu estim jazz oxyb franchis xyrem follow avdl posit top-line
once-nightli oxyb formul treatment excess daytim sleepi cataplexi narcolepsi
patient acknowledg potenti competit xyrem gener time continu
believ well posit narcolepsi market facilit smooth transit current xyrem patient
recruit new patient may benefit lower-sodium treatment option recal offer less sodium
xyrem view approv may option patient few/no cardio-metabol co-morbid
prefer once-nightli dose xyrem requir twice-nightli dose maintain outperform rate
potenti address
recent spoke manag atyr pharma life follow fda accept nda applic
phase studi patient sever respiratori complic believ could
demonstr efficaci patient manifest ard data compel get acceler approv
pathway occur time demonstr preclin efficaci acut lung inflamm mous model
compound mechan action could address heterogen patient ard phase trial
design rigor placebo-control arm await first patient enrolled/dos expect atyr provid
updat phase pulmonari sarcoidosi trial stay bullish
ongenti opicapon first comt inhibitor approv treatment parkinson diseas pd year set
new standard class ongenti offer signific clinic advantag first gener comt inhibitor
entacapon gener includ substanti increas time without troublesom dyskinesia
substanti reduct time includ entacapon non-respond improv toler less
diarrhea discolor bodili fluid improv efficaci safeti profil head-to-head studi vs entacapon
although stat sig greater conveni daili dose vs entacapon sever time per day
alreadi begun non-brand educ program initi brand ongenti launch later year detail
posit classical-lung updat aacr
matur phase interim result classical-lung trial continu illustr distinct potenti combin
immunotherapi pepinemab treat advanc non-smal cell lung cancer includ diseas resist
inhibitor monotherapi highlight grow evid durabl benefit rate diseas control remain encourag
sever patient cohort lack sign progress one year look forward near top-lin data
trial well potenti opportun see initi data studi solid tumor head
first take result
nxp releas earn monday even sales/ep line twice reduc consensu
revenu outlook tad street reduc estim sale outlook impli q/q
y/i channel inventori remain line target month second pre-announce management note opt
ship order distribut maintain consist histor inventori level nxp complet sale
voic audio solut asset gm decreas expect
await manag commentari nxp et earn call tuesday formal updat
delay mass product flagship iphon wsj reuter via wsj
offer scrap exclus deal end eu anti-trust probe reuter
action mitig nt downsid continu uncertainti valuat keep us sidelin
report adj ep vs estim gener in-lin oper america hpg
out-performance off-set downsid pressur higher expect tax rate expect demand trend
significantli deceler mid-march run rate april sale y/i envis demand trough
unknown shape recoveri respons worsen condit manag taken cost action full-year
save expect rang midpoint vs outlook remain cautiou acceler ep
pressur uncertain rebound trajectori earnings/cash flow downsid potenti offset prospect continu
re-rat intermediate-term remain construct upsid lever particularli differenti autom
tel report adjust ep lp includ predominantli impair charg
transport solut vs last year consensu vs guidanc
sale guidanc fell y-o-i organ vs guidanc vs
estim guid adjust om beat estim declin bp y-o-i adj op decreas
vs estim book bill covid impact hit march april outlook call sale
sequenti /- y-o-i sequenti decrement margin suggest ep
first cut guidanc anticip lower global auto product vs y-o-i impact overal
suppli chain impact relat covid
may biotech summit featur chemistri life process institut chicago il virtual confer
